Boehringer Ingelheim has joined the surge of companies entering the B-cell depletion space. But while its peers have largely ...

At the heart of the licensing deal is CUE-501, a bispecific molecule that can selectively deplete B cells to address ...

Christian Boehringer to hand over as Chairman of the Shareholders’ Committee to Hubertus von Baumbach Shashank Deshpande, Member of the Board of ...

Ingelheim: Boehringer Ingelheim has announced that Shashank Deshpande, member of the Board of Managing Directors, has been ...

Boehringer Ingelheim and Cue Biopharma (NASDAQ:CUE) announced Tuesday a research collaboration and a license agreement to ...

Boehringer Ingelheim and Cue Biopharma have announced a partnership worth $357m to develop and commercialise Cue’s ...

German family-owned drug major Boehringer Ingelheim and Cue Biopharma (Nasdaq: CUE) have announced a strategic research ...

Boston: Boehringer Ingelheim and Cue Biopharma, Inc. have announced a strategic research collaboration and license agreement ...

Boehringer Ingelheim and Cue Biopharma have entered a strategic research partnership and licence agreement to develop and commercialise the latter’s CUE-501 product candidate for autoimmune conditions ...